Targeting the CXCL9/CXCR3 axis may be a novel approach to modulate the immune situation in HCC, although more detailed mechanistic studies and clinical trials are still needed to fully understand its therapeutic impact and efficacy. The gene discussed is CXCR3; the disease is hepatocellular carcinoma.